BSI's Bos wants balanced view of Dagmar's high-risk proposals
This article was originally published in Clinica
Executive Summary
When it comes to the regulation of medical devices in the EU, the way forward certainly does not lie in market approval by a central government agency and by currently non-existing government agencies recognizing each other’s work in a decentralized market approval mechanism.